menu
    • menu
    [{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"GL-ONC1","moa":"Cancer cells (via oncolytic virus)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"GL-ONC1","moa":"Cancer cells (via oncolytic virus)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"GL-ONC1","moa":"Cancer cells (via oncolytic virus)","graph1":"Oncology","graph2":"Phase I","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"GL-ONC1","moa":"Cancer cells (via oncolytic virus)","graph1":"Oncology","graph2":"Phase I","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genelux \/ Genelux","highestDevelopmentStatusID":"6","companyTruncated":"Genelux \/ Genelux"},{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"GL-ONC1","moa":"Cancer cells (via oncolytic virus)","graph1":"Oncology","graph2":"Phase I","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Olvimulogene Nanivacirepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ GOG Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ GOG Foundation"},{"orgOrder":0,"company":"Genelux","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Private Placement","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Benchmark Company"},{"orgOrder":0,"company":"Genelux","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Private Placement","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Benchmark Company"},{"orgOrder":0,"company":"Genelux","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ GOG Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ GOG Foundation"},{"orgOrder":0,"company":"Genelux","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Guggenheim Securities"},{"orgOrder":0,"company":"Genelux","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Guggenheim Securities"},{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Olvimulogene Nanivacirepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Public Offering","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Titan Partners Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"Woodward Diversified Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Woodward Diversified Capital","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Woodward Diversified Capital"},{"orgOrder":0,"company":"Genelux","sponsor":"Newsoara Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Olvimulogene Nanivacirepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Newsoara Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Genelux \/ Newsoara Biopharma"},{"orgOrder":0,"company":"Genelux","sponsor":"Newsoara Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Olvimulogene Nanivacirepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genelux \/ Newsoara Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Genelux \/ Newsoara Biopharma"},{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"ELIAS Animal Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"V-VET1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genelux \/ ELIAS Animal Health","highestDevelopmentStatusID":"6","companyTruncated":"Genelux \/ ELIAS Animal Health"},{"orgOrder":0,"company":"Genelux","sponsor":"Andrew Lowy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"GL-ONC1","moa":"Cancer cells (via oncolytic virus)","graph1":"Oncology","graph2":"Phase I","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genelux \/ Andrew Lowy","highestDevelopmentStatusID":"6","companyTruncated":"Genelux \/ Andrew Lowy"}]

    Find Clinical Drug Pipeline Developments & Deals by Genelux

    Menu

    Genelux

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Bevacizumab,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genelux Aligns with FDA on Approval Pathway for Olvi-Vec in Platinum r/r Disease

                            Details : Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. It is being evaluated for the treatment of platinum resistant/refractory ovarian cancer.

                            Product Name : Olvi-Vec

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            March 25, 2025

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Bevacizumab,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Bevacizumab,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Titan Partners Group LLC

                            Deal Size : $10.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Genelux Prices $10.5M Underwritten Offering of Common Stock

                            Details : The net proceeds will used to support the company's late-stage product Olvi-Vec (olvimulogene nanivacirepvec), which is being evaluated for the treatment of Platinum r/r Ovarian Cancer.

                            Product Name : Olvi-Vec

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            March 25, 2025

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Bevacizumab,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Titan Partners Group LLC

                            Deal Size : $10.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Newsoara Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genelux, Newsoara Show Positive Phase 1b/2 Data for Olvi-Vec in SCLC

                            Details : Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. It is being evaluated for the treatment of small-cell lung cancer.

                            Product Name : Olvi-Vec

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            March 25, 2025

                            Lead Product(s) : Olvimulogene Nanivacirepvec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Newsoara Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Cisplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genelux Doses First Patient with Olvi-Vec in Phase 2 NSCLC Trial

                            Details : Olvi-Vec is a proprietary, modified oncolytic vaccinia virus, a stable DNA virus with a large engineering capacity. Genelux is developing Olvi-Vec in patients with advanced or metastatic NSCLC.

                            Product Name : Olvi-Vec

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            October 22, 2024

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Cisplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Newsoara Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint ...

                            Details : Olvimulogene Nanivacirepvec is a Microorganism drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            June 18, 2024

                            Lead Product(s) : Olvimulogene Nanivacirepvec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Newsoara Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Guggenheim Securities

                            Deal Size : $27.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Genelux Corporation Announces Pricing of $27.5 Million Underwritten Offering

                            Details : Proceeds will be used in the development of Olvi-Vec (olvimulogene nanivacirepvec), which is being evaluated in the late-stage clinical trial for the treatment of platinum-resistant ovarian cancer.

                            Product Name : Olvi-Vec

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            May 24, 2024

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Guggenheim Securities

                            Deal Size : $27.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Guggenheim Securities

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

                            Details : Proceeds will be used in the development of Olvi-Vec (olvimulogene nanivacirepvec), which is being evaluated in the late-stage clinical trial for the treatment of platinum-resistant ovarian cancer.

                            Product Name : Olvi-Vec

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            May 23, 2024

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Guggenheim Securities

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian ...

                            Details : Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in Phase 3 clinical trials for the treatment of platinum resistant/refractory ovarian cancer.

                            Product Name : Olvi-Vec

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            November 27, 2023

                            Lead Product(s) : Olvimulogene Nanivacirepvec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Bevacizumab,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Benchmark Company

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Genelux Corporation Announces $18 Million Private Placement

                            Details : Genelux will use the net proceeds for advancement of clinical programs, including the Phase 3 registrational trial of Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, non-pathogenic oncolytic vaccinia virus, in patients with platinum-resistant/refr...

                            Product Name : Olvi-Vec

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            June 12, 2023

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Bevacizumab,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Benchmark Company

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Benchmark Company

                            Deal Size : $33.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Genelux Corporation Announces $33 Million Private Placement

                            Details : The proceeds will advance clinical programs, including Phase 3 of Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, modified strain of the VACV, a stable DNA virus with a large engineering capacity, in patients with platinum resistant/refractory ova...

                            Product Name : Olvi-Vec

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            May 15, 2023

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Benchmark Company

                            Deal Size : $33.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth